Prolactin and growth hormone response to intracerebroventricular administration of the food opioid peptide gluten exorphin B5 in rats

Fanciulli, Giuseppe; Dettori, Alessandra; Tomasi, Paolo; Demontis, Maria Piera; Gianorso, S.; Anania, V.; Delitala, G.

doi:10.1016/s0024-3205(02)02036-2

Cited by 16 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased urinary excretion of gluten peptides in patients with schizophrenia has been observed previously (Reichelt and Landmark, 1995). Referred to as gluten exorphins, these peptides have been shown to have potent opioid-like properties and to affect hormonal balance, behavior, and learning in animal models (Fanciulli et al, 2005; Fanciulli et al, 2002; Takahashi et al, 2000). Therefore, the reported effect of gluten-free diet in some patients might be explained by the direct role some gluten peptides can exert on the nervous system.…”

Section: Discussionmentioning

confidence: 99%

Novel immune response to gluten in individuals with schizophrenia

Samaroo

Dickerson

Kasarda

et al. 2010

Schizophrenia Research

View full text Add to dashboard Cite

A link between celiac disease and schizophrenia has been postulated for several years, based primarily on reports of elevated levels of antibody to gliadin in patients. We sought to examine the proposed connection between schizophrenia and celiac disease by characterizing the molecular specificity and mechanism of the anti-gliadin immune response in a subset of individuals with schizophrenia. Blood samples from individuals with schizophrenia and elevated anti-gliadin antibody titer were examined for celiac disease-associated biomarkers, including antibodies to transglutaminase 2 (TG2) enzyme and deamidated gliadin peptides, as well as the HLA-DQ2 and -DQ8 MHC genes. The anti-gliadin antibody response was further characterized through examination of reactivity towards chromatographically separated gluten proteins. Target proteins of interest were identified by peptide mass mapping. In contrast to celiac disease patients, an association between the anti-gliadin immune response and anti-TG2 antibody or HLA-DQ2 and -DQ8 markers was not found in individuals with schizophrenia. In addition, the majority of individuals with schizophrenia and anti-gliadin antiboy did not exhibit antibody reactivity to deamidated gliadin peptides. Further characterization of the antibody specificity revealed preferential reactivity towards different gluten proteins in the schizophrenia and celiac disease groups. These findings indicate that the anti-gliadin immune response in schizophrenia has a different antigenic specificity from that in celiac disease and is independent of the action of transglutaminase enzyme and HLA-DQ2/DQ8. Meanwhile, the presence of elevated levels of antibodies to specific gluten proteins points to shared immunologic abnormalities in a subset of schizophrenia patients. Further characterization and understanding of the immune response to

show abstract

Section: Discussionmentioning

confidence: 99%

Novel immune response to gluten in individuals with schizophrenia

Samaroo

Dickerson

Kasarda

et al. 2010

Schizophrenia Research

View full text Add to dashboard Cite

show abstract

“…The Sassari, Italy, experiments were performed to test whether GEs could elicit biological activity in rats. Intracerebroventricular (ICV)-injection of gluten exorphin B5 into rats stimulated the release of prolactin through activation of opioid receptors [31,32]. Subsequently, efforts to determine the site of action of GE-B5 on prolactin secretion were conducted by pretreating male rats with naloxone methobromide (NMB), an opioid antagonist that does not cross the BBB [33]; NMB preadministration completely abolished the prolactin response.…”

Section: Transition From the Opioid Excess Theory To Potential Biomarmentioning

confidence: 99%

Stercobilin: A Putative Link between Autism and Gastrointestinal Distress?

Wood¹,

Charlebois²,

Sekera³

et al. 2019

Autism Spectrum Disorders - Advances at the End of the Second Decade of the 21st Century

Self Cite

View full text Add to dashboard Cite

Despite the increasing prevalence for its diagnosis in children, there are no clinical biomarkers of autism spectrum disorders (ASD). Herein a research journey is described that began by seeking evidence for the opioid excess theory of autism using mass spectrometry methods to screen human urine specimens and has evolved into the discovery of promising murine fecal biomarkers for ASD. Our results are consistent with an emerging body of evidence that shows that intestinal microflora from ASD subjects can be distinguished from controls, suggesting that metabolite differences due to the action of intestinal microbes may provide a means to identify ASD biomarkers.

show abstract

“…In animal models, GE-B5 has been shown to stimulate the glucose-induced insulin release after intragastric administration [14]. It was previously demonstrated that GE-B5 can play a regulatory role on pituitary secretion, since it markedly stimulates Prolactin secretion in rats [15,16], probably via a reduction in neurotransmitter release at the hypothalamic level.…”

Section: Introductionmentioning

confidence: 99%